Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.


Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?


Please Try Again {{ error }}

Send my password

An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Stock Quote Today & Recent News BioMarin Pharmaceutical Inc. BMRN

BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) is poised to potentially launch in the 2022-23 timeframe.

The Power Play by The Market Herald
< Previous Video {{moreVideoText}} Next Video >

Stock Price Chart (NDAQ:BMRN)

Fundamentals Snapshot (NDAQ:BMRN)

Current News (NDAQ:BMRN)

BioMarin Announces Record Revenues in Second Quarter 2022; Increases Full-year 2022 Top and Bottom-line Guidance

PR Newswire 5 days ago

BioMarin to Host Second Quarter 2022 Financial Results Conference Call and Webcast on Wednesday, August 3, at 4:30pm ET

PR Newswire July 20, 2022

BioMarin Presents Findings from Studies of Valoctocogene Roxaparvovec, Investigational Gene Therapy, at the International Society on Thrombosis and Haemostasis (ISTH) 2022 Congress July 9-12, Including 4 Oral and 2 Poster Presentations

PR Newswire July 11, 2022

BioMarin Receives Positive CHMP Opinion in Europe for Valoctocogene Roxaparvovec Gene Therapy to Treat Adults with Severe Hemophilia A

PR Newswire June 24, 2022

BioMarin Announces the Ministry of Health, Labor and Welfare (MHLW) in Japan Granted Approval for VOXZOGO® (vosoritide) for Injection for the Treatment of Children with Achondroplasia, Whose Growth Plates are Not Closed

PR Newswire June 21, 2022

BioMarin Announces Favorable Results from Global Phase 2 Study of VOXZOGO(TM) (vosoritide) for Injection in Infants and Young Children with Achondroplasia at The Endocrine Society Annual Meeting, ENDO 2022 (June 11-14), in Atlanta

PR Newswire June 13, 2022

BioMarin Announces Durable Hemostatic Efficacy Maintained Over 6 years in Ongoing Phase 1/2 Study of Valoctocogene Roxaparvovec, Investigational Gene Therapy for Hemophilia A

PR Newswire May 31, 2022

BioMarin Hires Pharmaceutical Industry Leaders in Marketing and Accounting to Fill Strategic Roles Supporting Company's Growth Plans

PR Newswire May 5, 2022

BioMarin to Present Findings from Ongoing Studies of Valoctocogene Roxaparvovec, Investigational Gene Therapy, at the World Federation of Hemophilia 2022 World Congress, May 8-11, 2022, Including Five Platform Presentations

PR Newswire May 5, 2022

Opinion & Analysis (NDAQ:BMRN)

How sick will Brexit make biotech and pharma?

The Life Sciences Report June 29, 2016

The Calandra Report: Watch this hot tub!

Thom Calandra January 10, 2014

Big Pharma has a big problem and merger mania is heating up

Marc Lichtenfeld July 29, 2010

Bullboard Posts (NDAQ:BMRN)

Bulls on Parade

Get ready for the correction; getting close to day 3 
hart.marco - August 21, 2020

Holding Strong

in the face of overall weakness.strong management leads to strong results.great job here!...again,if this was a vancouver,canada bio-tech...
seldomseen1 - March 7, 2008

RE: moving forward

new highs we come.if this was a vancouver biotech(LOL)/managements there would roll this back..they are too funny LOL.
seldomseen1 - February 1, 2008

moving forward

coming off highs,still very strong going forward.
seldomseen1 - January 29, 2008

Coming of HIGHS

but what a run.if this was a VANCOUVER bio-tech..managment would have rolled the stock back LOL.Biomarin.nice work.
seldomseen1 - January 23, 2008

Always a first

first down .50$...what a ride.great work.
seldomseen1 - January 14, 2008